And the winner of Startup Battlefield at Disrupt 2026 is: Intero Biosystems
Intero Biosystems wins TechCrunch Disrupt Startup Battlefield 2026 with GastroScreen, a product for testing drugs and compounds.
Intelligence analysis by Qwen 2.5 (3B)

TechCrunch announces the winner of the Startup Battlefield at TechCrunch Disrupt 2026, which is Intero Biosystems.
Intero Biosystems won a big contest at TechCrunch Disrupt 2026. They make a special tissue that looks like a part of the gut. Companies can use this tissue to test medicines without hurting animals. Intero Biosystems won a prize for their cool new product.
Analysis
{"#Intero Biosystems":"Intero Biosystems, founded by Charlie Childs and Madeline Eiken, spun out of the University of Michigan. The company focuses on developing 1mm human intestinal 'organoids,' lab-grown tissue that mimics the gut. This technology offers a new way to study how drugs and other compounds might affect the human body before they are tested in people. The startup sells its flagship product, GastroScreen, to pharmaceutical, biotech, food, and chemical companies for testing drugs and other compounds. The company's success at TechCrunch Disrupt 2026 underscores the potential of this innovative technology.","#GastroScreen":"GastroScreen is a product that allows companies to test drugs and other compounds on lab-grown human intestinal tissue. This technology could revolutionize drug testing and research by providing a more accurate and ethical alternative to animal testing.","#Startup Battlefield":"The Startup Battlefield at TechCrunch Disrupt 2026 is a competition where startups pitch their ideas to a panel of judges. Intero Biosystems was one of the top 20 startups selected to compete, and their success in this competition highlights the potential of their GastroScreen product."}
Key points
- Intero Biosystems won the Startup Battlefield at TechCrunch Disrupt 2026
- Their product, GastroScreen, is used for testing drugs and compounds on lab-grown human intestinal tissue
- The company is based in Denver and was founded by Charlie Child and Madeline Eiken
If Intero Biosystems' GastroScreen product is successful, it could lead to more ethical and accurate drug testing, which could benefit both companies and animal welfare.
If GastroScreen doesn't work as expected, it could delay the development of new medicines and harm the startup's reputation.



